CDNA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -8.94% compared to CareDx's net margin of --. CareDx's return on equity of -49.52% beat Perspective Therapeutics's return on equity of --.

CareDx has a consensus price target of $35.20, signalling upside risk potential of 61.84%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than CareDx, analysts believe Perspective Therapeutics is more attractive than CareDx.

CareDx has a beta of 1.840, which suggesting that the stock is 84.01% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $82.9M, which are larger than Perspective Therapeutics quarterly revenues of --. CareDx's net income of -$7.4M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, CareDx's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.60x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -8.94% compared to CareDx's net margin of 10.05%. CareDx's return on equity of -49.52% beat Electromed's return on equity of 15.62%.

CareDx has a consensus price target of $35.20, signalling upside risk potential of 61.84%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 11.56%. Given that CareDx has higher upside potential than Electromed, analysts believe CareDx is more attractive than Electromed.

CareDx has a beta of 1.840, which suggesting that the stock is 84.01% more volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $82.9M, which are larger than Electromed quarterly revenues of $14.7M. CareDx's net income of -$7.4M is lower than Electromed's net income of $1.5M. Notably, CareDx's price-to-earnings ratio is -- while Electromed's PE ratio is 41.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.60x versus 4.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Personalis has a net margin of -8.94% compared to CareDx's net margin of -152.04%. CareDx's return on equity of -49.52% beat Personalis's return on equity of -67.2%.

CareDx has a consensus price target of $35.20, signalling upside risk potential of 61.84%. On the other hand Personalis has an analysts' consensus of $7.58 which suggests that it could grow by 24.53%. Given that CareDx has higher upside potential than Personalis, analysts believe CareDx is more attractive than Personalis.

CareDx has a beta of 1.840, which suggesting that the stock is 84.01% more volatile than S&P 500. In comparison Personalis has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.655%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Personalis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Personalis pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $82.9M, which are larger than Personalis quarterly revenues of $25.7M. CareDx's net income of -$7.4M is higher than Personalis's net income of -$39.1M. Notably, CareDx's price-to-earnings ratio is -- while Personalis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.60x versus 3.72x for Personalis. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -8.94% compared to CareDx's net margin of -17.98%. CareDx's return on equity of -49.52% beat Xtant Medical Holdings's return on equity of -35.98%.

CareDx has a consensus price target of $35.20, signalling upside risk potential of 61.84%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than CareDx, analysts believe Xtant Medical Holdings is more attractive than CareDx.

CareDx has a beta of 1.840, which suggesting that the stock is 84.01% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

CareDx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareDx pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

CareDx quarterly revenues are $82.9M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. CareDx's net income of -$7.4M is lower than Xtant Medical Holdings's net income of -$5M. Notably, CareDx's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareDx is 3.60x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.